COVID-19 Archives - Page 14 of 15

Markets

BTIG ups Centogene PT to $23 from $18

BTIG raised its price target for Centogene (NASDAQ:CNTG) to $23 from $18, citing a “solid execution” in its pharma and diagnostics segments in 2019. The stock closed at $18.69 on April 23. Analyst Sung Ji Nam writes...

April 24, 2020

Developments

Charlotte’s Web donates $1-million (US) worth of CBD in memory of Charlotte Figi

Charlotte’s Web (TSX:CWEB; OTC:CWBHF) donated $1-million (US) worth of CBD product to individuals who rely on the company’s products and may be struggling financially as a result of the COVID-19 pandemic. The...

April 21, 2020

Developments

Karyopharm Therapeutics doses first COVID-19 patient in selinexor study

Karyopharm Therapeutics (NASDAQ:KPTI) dosed the first patient in a Phase 2 clinical study evaluating low-dose oral selinexor in hospitalized patients with severe COVID-19. Selinexor is designed to block XPO1, a...

April 20, 2020

Developments

Anixa Biosciences in COVID-19 development pact with OntoChem

Anixa Biosciences (NASDAQ:ANIX) entered a strategic collaboration with OntoChem GmbH to discover and develop anti-viral drug candidates for COVID-19. “We believe that newly designed drugs that are purposefully developed...

April 20, 2020

Developments

Vanda Pharma enrolls first patient in Phase 3 COVID-19 trial

Vanda Pharmaceuticals (NASDAQ:VNDA) enrolled the first patient in its Phase 3 trial assessing tradipitant for the treatment of neurogenic inflammation of the lung, secondary to COVID-19 infection. The study will enroll...

April 15, 2020

Developments

Chembio gets FDA emergency use authorization for serological COVID-19 test

The FDA granted emergency use authorization to Chembio Diagnostics’ (NASDAQ:CEMI) dual path platform (DPP) COVID-19 system. The system is a serological point-of-care test and analyzer that provides numerical readings...

April 15, 2020

Markets

Canaccord ups Vapotherm PT to $20 from $14

Canaccord Genuity raised its price target for Vapotherm (NYSE:VAPO) to $20 from $14, citing preannounced first quarter results that beat expectations. The stock closed at $16.65 on April 13. Vapotherm is focused on the...

April 14, 2020

Markets

Brookline starts Bellerophon Therapeutics at buy; PT $35

Brookline Capital Markets initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and $35 price target. The stock closed at $11.91 on April 13. Bellerophon is developing inhaled nitric oxide...

April 14, 2020

Markets

HCW cuts Entasis Therapeutics PT to $5 from $18 on dilution

H.C. Wainwright slashed its price target for Entasis Therapeutics (NASDAQ:ETTX) to $5 from $18, but maintained its “buy” rating, citing a major financing that carries substantial dilution. The stock closed at $2.64 on...

April 14, 2020

Feature

NanoViricides targeting multiple types of viral infection with nanomedicine platform

Using its nanomedicine platform and the capabilities of its cGMP manufacturing facility, NanoViricides (NYSE American: NNVC) is developing therapeutics for a variety of viral infections, including herpes simplex viruses...

April 14, 2020

Tag - COVID-19

BTIG ups Centogene PT to $23 from $18

Charlotte’s Web donates $1-million (US) worth of CBD in memory of Charlotte Figi

Karyopharm Therapeutics doses first COVID-19 patient in selinexor study

Anixa Biosciences in COVID-19 development pact with OntoChem

Vanda Pharma enrolls first patient in Phase 3 COVID-19 trial

Chembio gets FDA emergency use authorization for serological COVID-19 test

Canaccord ups Vapotherm PT to $20 from $14

Brookline starts Bellerophon Therapeutics at buy; PT $35

HCW cuts Entasis Therapeutics PT to $5 from $18 on dilution

NanoViricides targeting multiple types of viral infection with nanomedicine platform

Subscribe